2013 Fiscal Year Final Research Report
Establishment of personalized antiemetic treatment based on genetic polymorphisms
| Project/Area Number |
24790162
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | University of Shizuoka |
|---|
Principal Investigator |
TSUJI Daiki 静岡県立大学, 薬学部, 助教 (90565615)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Keywords | 薬物応答性 / 制吐療法 / 臨床薬理学 / グラニセトロン / アプレピタント |
|---|
| Research Abstract |
Chemotherapy-induced nausea and vomiting (CINV) are one of the most unpleasant non-haematological adverse effects that affect the well-being of cancer patients. The aim of this study was to evaluate the association between the antiemetic efficacy and the ABC polymorphisms and clarify the risk of CINV. Patients receiving highly emetogenic chemotherapy were examined for antiemetic responses to aprepitant in combination with granisetron and dexamethasone. The multivariate logistic regression analyses showed that female gender, age <50 years, ABCB1 1236 TT , and ABCG2 421 AA were associated with antiemetic treatment failure in the acute phase. In contrast, only female gender was associated in the delayed phase.
|
